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Normal adult T  lymphocytes control the rate of Epstein-Barr virus (EBV)Linduced 
proliferation of B cells (1, 2). T  cells of patients with rheumatoid arthritis (RA) do not 
regulate  the  in  vitro  EBV  infection  as  efficiently,  and  EBV-induced  B  cell  lines 
develop more rapidly  from RA peripheral  blood lymphocytes (3,  4).  There is also 
evidence that  activated T  cells produce lymphokines capable of modulating  EBV- 
induced lymphoblast transformation  (5,  6). Therefore, we have sought to determine 
whether  the  defective  regulation  by RA  T  cells  is  associated  with  a  difference  in 
lymphokine production or activity. 
Because mixed leukocyte reactions (MLR) generate considerable lymphokine activ- 
ity, and because the autologous MLR appears to be involved in immunoregulatory 
mechanisms (7-11), supernatants from allogeneic and autologous MLR cultures were 
tested for their effects on EBV-induced B cell proliferation. We found that RA and 
normal  T  cells  respond  equally  to  allogeneic  challenge  with  the  production  of a 
lymphokine  that  effectively controls  the  lymphoblast  transformation.  Autologous 
MLR supernatants from normal cells also effectively slow the rate of B cell prolifer- 
ation, but RA T  cells are specifically deficient in the production of this immunoreg- 
ulatory lymphokine when stimulated by autologous non-T cells. The lymphokine has 
the physicochemical characteristics of human gamma interferon, its activity is mim- 
icked  by  gamma  interferon  added  to  EBV-infected  B  cells,  and  the  lymphokine 
activity is  removed  from culture  supernatants  reacted  with  antibodies  specific  for 
gamma  interferon.  Thus,  the  defective  regulation  of  EBV-induced  lymphoblast 
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transformation by T  cells from patients with RA may he due to diminished generation 
of gamma interferon by the T  cells interacting with EBV-infected B cells. 
Materials and Methods 
Subjects.  Heparinized venous blood was obtained from 26 patients with definite or classical 
seropositive  RA  (12) between  the  ages  of 25  and  70  yr  (mean  56  yr);  12  patients  with 
spondyloarthropathies (5 with ankylosing spondylitis, 3 with Reiter's syndrome, and 4 with 
psoriatic arthritis), mean age 43 yr (range 21-66 yr), all taking nonsteroidal anti-inflammatory 
agents; and 32 normal blood donors between the ages of 17 and 84 gr (mean 40 yr). All but one 
of the RA patients were taking nonsteroidal anti-inflammatory  agents and, in addition, about 
one-half of them received either gold or D-penicillamine. Eight RA patients were also being 
treated with small doses (<10 mg/d) of prednisone. 
Cell Separation.  Peripheral blood mononuclear  cells were obtained from heparinized venous 
blood by Ficoll-Hypaque density gradient centrifugation, and T cells were separated from non- 
T cells by erythrocyte (E)-rosetting with neuraminidase-treated  sheep erythrocytes as previously 
described (3). The non-T cell population was composed of 25-30% immunoglobulin-bearing 
cells as determined by direct immunofluorescence  with F(ab')2 goat anti-human immunoglob- 
ulins (N. L. Cappel Laboratories, Cochranville, PA), 50-60% esterase-positive cells  (13), and 
<2% E-rosetting cells. The T  cell populations contained <5% immunoglobulin-bearing  cells. 
For adherent cell depletion, the non-T cells were resuspended at a density of 1.0 X  10V/ml in 
RPMI plus 20% fetal calf serum (FCS) and plated in 2-ml aliquots into 60-mm-diam glass petri 
dishes. After incubating at 37°C for 1 h, the nonadherent cells are removed by aspiration and 
are further depleted of adherent cells by passage through G-10 Sephadex columns (14). The 
resultant adherent cell-depleted non-T population contained <l% esterase-positive cells and 
50-70% surface immunoglobulin-bearing  cells. 
Cytofluorographic Sorting.  Double-E-rosetted T  cells are reacted with each monoclonal anti- 
body  (OKT4  and OKT8;  Orthoclone, Ortho  Pharmaceutical, Raritan,  N  J)  using  1 /~1  of 
antibody plus 1 /11 of 10% y-globulin-free horse serum (y-GFHS)-RPMI (Gibco Laboratories, 
Grand Island Biological Co.,  Grand Island, NY)  per  1 ×  106 cells.  This cell  suspension is 
incubated at 0°C for 30 min, then layered over 5 ml of cold y-GFHS, pelleted at 400 g for  10 
min, and washed twice with 10% y-GFHS-RPMI. The cells to be sorted are resuspended in 2 
/zl  of  rabbit  anti-mouse IgG-fluorescein isothiocyanate  (1:40  dilution)  per  1  X  106  cells, 
incubated in the dark at 0°C for 30 min, relayered over y-GFHS, and pelleted at 400 g for  10 
min. After two washes,  the cells are resuspended at a density of 2.5 X  106 cells/ml in RPMI- 
20% FCS. An aliquot of purified T cells (1-2 X 106 cells), stained in parallel with a nonreactive 
mouse myeloma protein of the same subclass as the monoclonal antibody (RPC5), provides 
control cells for establishing the gating settings on the cell sorter (Ortho model 50D with an 
argon laser).  The yield of OKT8  + cells has been 0.5-2 ×  10  s cells/ml of blood with 94-98% 
purity (<1%  OKT8  + cells in the OKT8- population). For OKT4  +, the yield has been 2-4 X 
l0  s cells/ml of blood with 95-99% purity (<<1% OKT4  + cells in the OKT4- population). 
MLR Cultures.  Non-T cells were treated with 25 btg/ml mitomycin C (Sigma Chemical Co., 
St.  Louis, MO), for 60 min at  37°C, followed  by three washes  in RPMI-10% FCS.  1 X  105 
mitomycin-treated non-T cells were cultured with 2 X 10  ~ autologous or allogeneic T  lympho- 
cytes  in 0.2 ml RPMI  1640 supplemented with  10% FCS, 2 mM glutamine, and peaicillin- 
streptomycin at 5,000 U/ml (R-FCS) in fiat-bottomed Linbro plates 76-001-05; Flow Labora- 
tories,  Hamden, CT. [aH]Thymidine incorporation [1 gCi/well; Schwarz/Mann Div., Becton, 
Dickinson & Co., Orangeburg, N  J) was added during the last  18 h of incubation. The cultures 
were harvested on day 7 with a semi-automated multiple sample harvester (MASH) device. 
Data are expressed  as the mean 3H counts per minute of triplicate cultures. 
Preparation of Supernatants.  MLR-derived supernatants were produced by T  cells that were 
stimulated by mitomycin C-treated non-T cells in 2 ml R-FCS at a  responder-to-stimulator 
ratio of 2:1 and a total cell density of 106 cells/ml. After 72 h, the supernatants were recovered 
and filtered through 0.45-/~m membranes (Millipore Corp., Bedford, MA). The supernatants 
were stored at -80°C until used. 
Virus.  Transforming virus was obtained from the supernatants of the EBV-secreting B95-8 
marmoset lymphoblastoid cell line (15), as described previously (3). The supernatant lympho- HASLER ET AL.  175 
cyte-transforming titer, calculated as described by Reed and Muench  (16),  was 4.4 logx0 50% 
transforming doses/ml. 
EB VInterference Assay.  Cells were infected with EBV by adding 0.05 ml ofB95-8 supernatant 
to 1 ×  l0  s double-rosetted non-T lymphocytes from normal donors in 1 ml R-FCS, followed by 
incubation at 37°C for 60 min in a  humidified 5% CO2-in-air atmosphere. After three washes 
in  R-FCS,  the  infected cells were cultured  at  5  ×  104  cells/well in  flat-bottomed, 96-well 
microtiter plates in 0.2 ml R-FCS alone or R-FCS mixed with MLR supernatant at 1:2 or 1:4 
final dilutions. After 5-6 d,  75-100/zl of medium was removed from the upper half of each 
culture and replaced with an equal volume of fresh complete medium. 
EBV-induced cell proliferation was assessed by measuring [ZH]thymidine incorporation on 
day 10 or as described in individual experiments. The data obtained are expressed as percent 
suppression which are calculated as percent suppression =  1 -  [(cpm in MLR supernatant- 
treated cultures)/(cpm in control cultures)]  ×  100. Factors produced by lymphocytes of the 
same individual in different experiments were similarly effective against EBV-infected lympho- 
cytes from a panel of different cell donors. For example, auto-MLR supernatants from subject 
BF, generated on three different occasions, 12 wk apart, and tested in I0 different experiments 
with B lymphocytes from 7 different donors caused a mean suppression of 67 _+ 3 % (SE). 
Interferon and Anti-Interferon  Antibodies.  Human leukocyte alpha interferon standard (G-023- 
901-527),  human  fibroblast reference beta interferon  (G-023-902-527), and sheep antisera to 
human alpha interferon standard (G-026-502-568) and to human beta interferon (G-028-501- 
568)  were  provided by  the  National  Institute of Allergy and  Infectious Diseases. Gamma 
interferon,  prepared  as  previously  described  (17),  was  kindly  provided  by  Dr.  J.  Vilcek, 
Department  of  Microbiology,  New  York  University  Medical  Center,  New  York.  Rabbit 
antiserum to human gamma interferon (18) and a different gamma interferon preparation were 
provided by Dr. G. J.  Stanton, University of Texas Medical Branch, Galveston, TX.  Mouse 
monoclonal  antibody  against  human  gamma  interferon  (19) was  provided  by  Dr.  H.-K. 
Hochkeppel, Gesellschaft f/Jr Biotechnologische Forschung mbH, Braunschweig, Federal Re- 
public of Germany, and a goat antibody against 45,000-mol wt human gamma interferon was 
provided by Dr. M. de Ley and Dr. A. Billiau, Rega Institute for Medical Research, University 
of Leuven, Leuven, Belgium (20). 
Interferon Assay.  A quantitative inhibition ofcytopathic effect assay for human interferon, as 
described by Epstein et al. (2 I), was used with A-549 monolayer cells (derived from a carcinoma 
of the lung) and encephalomyocarditis virus as the challenge virus. 
Staphylococcus Bacteria Strain Cowan I Interference Assay.  Staphylococcus bacteria strain Cowan 
I, formaldehyde- and heat-killed, (Pansorbin; Calbiochem-Behring Corp., San Diego, CA) was 
added to double-rosetted non-T cells at concentrations of 0.001-0.01 vol/vol. B cells (5 ×  104-1 
×  105 cells/well) were cultured with Pansorbin with or without auto-MLR supernatants at 1:2 
or  1:4  final  dilutions.  DNA  synthesis was  assessed  on  day 4  by  measuring  [ZH]thymidine 
incorporation. The data obtained are expressed as percent suppression, and are calculated as 
described above. 
Results 
During the autologous MLR, cells from healthy donors release a  factor(s) into the 
culture medium that retards the rate of EBV-induced B  lymphoblast out-growth in 
a dose-related manner (Fig. 1). EBV-induced B cell proliferation, measured  10 d after 
virus infection, was inhibited 50  +  3%  (mean +  SE)  by dilutions of 72-h auto-MLR 
supernatants generated by cells from 32 normal donors. Studies of the time course of 
factor generation revealed that  maximum  suppression was observed in supernatants 
obtained  after  72  h  in  the  auto-MLR.  Proliferation  was  inhibited  15%  by  24-h 
supernatants,  25%  by 48oh supernatants,  and 48%  by 72-h supernatants  from  auto- 
MLR  generated by cells from four normal donors. Longer culturing of the auto-MLR 
through 6 d  did not yield more inhibitory activity. 
In contrast  to the inhibitory activity generated  by cells from  normal  donors, RA 
auto-MLR  supernatants  were  ineffective regulators;  72-h supernatants  from  26  RA 176  IMPAIRED REGULATION OF  EPSTEIN-BARR VIRUS OUTGROWTtt 
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Fro.  1.  Suppression  of EBV-induced B cell proliferation by dilutions of a 72-h supernatant  from 
a  normal  auto-MLR.  Results  are expressed  as  the mean  percent  suppression  of [SH]thymidine 
incorporation compared  with control cultures  10  d  post-EBV infection  (mean control counts  = 
59,109). Error bars indicate the SEM of quadruplicate cultures. 
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Fro.  2.  Effect of autologous MLR-derived supernatants from normal subjects  (Nt), patients with 
spondyloarthropathies  (SA), and patients with rheumatoid arthritis  (RA) on EBV-induced B cell 
proliferation.  Results  are expressed as the mean percent suppression  of the [aH]thymidine  incorpo- 
ration compared with control cultures at  10 d post-EBV infection  (mean control counts from 32 
experiments  =  50,181  cpm).  Each  point  represents  the average of the  results  of three  separate 
experiments for each subject  done at different  times. Error bars represent  the mean +- SEM for all 
individuals in the designated groups. 
patients  inhibited  EBV-induced  B  cell  proliferation  only  8  ±  3%  (Fig.  2).  The 
inhibitory activity did not  increase  in RA supernatants  obtained within up  to 5  d  of 
auto-MLR.  Diminished lymphokine activity from RA cells could not be attributed  to 
the drugs taken by the patients. Auto-MLR  supernatants  from  12 subjects with active 
spondyloarthropathies  receiving  similar  nonsteroidal  anti-inflammatory  drugs  in- 
hibited  EBV-induced  DNA  synthesis  (50  ±  2%)  as well as those  from normal  donors 
(Fig.  2).  The  lack of inhibitory  activity in  auto-MLR  supernatants  was  observed  in 
samples  from  18 RA  patients  who were not  treated  with corticosteroids  (6  -  3%),  as 
well as those from 8  RA patients  taking prednisone  at _<10 rag/(12  ±  5%).  Similarly, HASLER  ET  AL  177 
there was no difference between the  14 patients receiving gold or o-penicillamine (8 
+  3%) and the  12 RA patients not taking those drugs (8 +  4%). Although there is a 
modest decrease in inhibitory activity in auto-MLR supernatants from older subjects 
(43 +  3% mean suppression in supernatants  from  15 donors over age 40 compared 
with 52 +  2% suppression in those from donors younger than 40), age cannot account 
for the striking differences between RA and normal supernatants. 
Supernatants of activated lymphocytes are known to contain a variety of lympho- 
kines,  some with  stimulatory capacities and  others suppressive.  We considered the 
possibility that a difference in the balance between helper and suppressor lymphokines 
or  the  generation  of inhibitors  of the  suppressive  lymphokines  might  explain  the 
discrepancy observed when RA and normal T  cells were stimulated  by autologous 
mononuclear cells.  However, mixing nonsuppressive RA-cell-produced MLR super- 
natants  with suppressive supernatants  from normal cells failed to demonstrate any 
signs of competition (Fig. 3). 
The inhibitory factor(s) in the auto-MLR supernatants exerts its effects relatively 
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FIG.  3.  The  effect  of mixing  RA-cell-derived  auto-MLR  supernatants with  supernatants from 
normal auto-MLR on the suppression of EBV-induced B cell  proliferation. Dilutions of a  normal 
supernatant were added  to  EBV-infeeted  non-T cells  alone or in the presence of a  constant  1:2 
dilution  of an  RA supernatant.  Results are  expressed as  the  mean  percent  suppression of [SH] 
thymidine incorporation compared with control cultures  10  d  post-EBV infection  (mean control 
counts =  32,543).  Error bars indicate the SEM of quadruplicate cultures. 
.o 
03-  0 
UJ 
50 
30 
20 
10 
2  3  4  6  9 
Length of Culture (days) 
Flo.  4.  The  effect  of a  delayed  addition  of a  supernatant  from  a  normal  auto-MLR  on  the 
suppression of EBV-induced B cell  proliferation. Supernatants were added  at the times indicated 
after  EBV  infection  of normal  non-T lymphocytes,  Results are  expressed as  the  mean  percent 
suppression of [nH]thymidine incorporation compared with control cultures 10 d post-EBV infection 
(mean control counts =  53,385  cpm). Error bars indicate the SEM of quadruplicate cultures. 178  IMPAIRED  REGULATION OF  EPSTEIN-BARR VIRUS OUTGROWTH 
TABLE  I 
Identification of the T Cells Required  for the Generation of Supernatant-med~ated 
Inhibition of EB V-induced B Cell Proliferation 
Auto-MLR*  Supernatant~ 
Percent suppres-  Interferon¶  Responder  Stimulator  sion[i 
U/ml 
E-RFC  -  17 -  3  NT 
+  76 +  4  37 
OKT4  +  -  4 +  12  NT 
+  67 +  3  23 
OKT8  +  -  0 +- 3  NT 
+  18 +- 8  <1 
Non-T  -  7 +  2  NT 
* Auto-MLR were established  with 106 responder  cells/ml with (+) or without (-) 5 
×  l0  s mitomycin-treated non-T stimulator cells/ml. 
:~ Auto-MLR supernatants were obtained after 72 h of culture. 
§ E-RFC -  twice-E-rosetted  T  cells; OKT4  + and OKT8  + cells were obtained with 
the fluorescence-activated  cell sorter as described  in Materials and Methods. Non-T 
indicates  peripheral blood mononuclear cells depleted of E-rosetting ceils. 
II Results are expressed  as the mean +  SEM % suppression  of EBV-induced B cell 
proliferation compared  with  control  cultures  at  10  d  post-EBV  infection  (mean 
control counts =  89,990 corn). 
¶ Data is expressed as the mean of two determinations of interferon activity assayed 
as  described  in  Materials  and  Methods.  Units  expressed  as  equivalents  to  the 
antiviral effect of the international standard for alpha interferon. 
early  after  EBV  infection.  The  susceptibility  of the  infected  cells  to  inhibition  by 
supernatants  is maximal  immediately after infection and persists  for 3  d. Addition of 
supernatants  >--96  h  after  EBV  infection  had  little  or  no  effect  on  subsequent 
lymphoblast  proliferation  (Fig.  4).  Similarly, auto-MLR  supernatants  had  no signif- 
icant effect on the proliferation of previously established permanent  B  lymphoblastoid 
cell lines. Thus,  the inhibition of EBV-induced  B  cell proliferation does not appear  to 
be due to direct inhibition of DNA  synthesis or other biochemical events required for 
cell proliferation. 
The  inhibitory  potency  of the auto-MLR  supernatants  is not  related  to  the  DNA 
synthetic response of the T  cells to autologous non-T cell stimulation. The correlation 
coefficients obtained  when  comparing  [aH]thymidine  incorporation  on  day  7  of the 
auto-MLR  with the inhibitory activity of day 3 supernatants  were r =  0.31  in samples 
from  normal  subjects  and  r  --  0.11  in  cultures  from  RA  patients.  In  addition,  the 
mean DNA  synthetic response of RA cells in the auto-MLR,  11,359  cpm +  2,329  SE, 
and  the  mean  response  in  normal  cell populations,  13,535  cpm  +  2,102  SE  did  not 
differ significantly.  Finally, the  generation  of the  inhibitory  factor in  the  auto-MLR 
does  not  require  T  cell  proliferation.  Pretreatment  of  the  responder  T  cells  with 
mitomycin  C  at  a  concentration  that  inhibited  auto-MLR-induced  DNA  synthesis 
>90% and X  irradiation of the T  cells with 2,000 rad, eliminating their DNA  synthetic 
response  to autologous  cell stimulation,  did not  interfere with factor elaboration. 
The types oft  cells required for the generation of the inhibitory factor was analyzed 
by  separating  T  cells  from  normal  donors  into  OKT4 +-  and  OKT8+-enriched 
subpopulations  using  a  fluorescence-activated  cell  sorter.  When  OKT4 +  cells  were HASLER  ET  AL.  179 
used as responders  in  the auto-MLR,  the supernatant  inhibitory activity was essen- 
tially the same as that obtained with the unfractionated T  cells (Table I). The OKT8 ÷ 
ceils generated little suppressive activity in response to autologous non-T cells. 
Allogeneic MLR also generate a  factor(s) that suppresses EBV-induced lymphoblast 
outgrowth.  In fact, the inhibitory activity was stronger in allo-MLR-derived super- 
natants  than  in  those generated in the auto-MLR.  However, unlike the auto-MLR 
responses, ceils from  RA patients produce as much  inhibitory activity on allogeneic 
stimulation as do normal T  cells (Fig. 5 A). When serially diluted, the RA and normal 
T  cell  supernatants  lost  their  suppressive  activities  in  parallel.  The  most  potent 
supernatants retained their activity to dilutions of up to 1:200. The inhibitory activity 
generated in the auto- and allo-MLR have similar physicochemical properties. They 
are heat labile (heating to 56°C for 30 min removed ~60% of the effect, whereas after 
60  min  all  inhibitory  activity  was  lost),  and  are  inactivated  at  pH  2.0  (Fig.  6). 
Chromatography on Sephadex G-100 revealed that the active factor has a  molecular 
weight of-50,000  (Fig. 7). 
Because  RA T  cells produce  inhibitory factors when  challenged  in  the  MLR  by 
allogeneic cells  but  not  autologous  ceils,  we  examined  the  autologous  non-T  cell 
stimulator population for its contribution  to  the  RA defect.  72-h  auto-MLR  super- 
natants from intact and adherent cell (AC)-depleted cultures, diluted 1:2, were tested 
for their effects on  DNA synthesis in  B  cells  10  d  after virus infection  (Fig. 8).  The 
inhibitory activity in supernatants produced by cells from nine normal donors did not 
change significantly after AC depletion  (58  ±  4%  SE before and  65  4-  7%  after AC 
depletion). In supernatants  from eight RA patients, by contrast, inhibition of EBV- 
induced DNA synthesis increased from  11  ±  6  to 52 4- 6% after monocyte depletion. 
Thus,  RA cells are able to respond to autologous stimulation with the generation of 
a  factor that can inhibit EBV-induced B cell proliferation, but their capacity to do so 
is diminished in the presence of autologous AC. 
We  have  examined  the  relationship  between  the  inhibitory  lymphokines  and 
FIc.  5.  (A) Suppression of EBV-induced  B cell proliferation  by the addition of 1:2 dilutions  of 
auto-MLR- and allo-MLR-derived  supernatants  from RA and normal (N) subjects. Results are 
expressed as the mean percent suppression of [ZH]thymidine incorporation  compared with control 
cultures at  10 d post-EBV infection. Error bars indicate the SEM of quadruplicate cultures. The 
numbers of subjects tested in each group are shown above the bars. (B) Suppression of Staphylo- 
coccus bacteria strain Cowan I-induced B cell proliferation by the addition of 1:2 dilutions ofauto- 
MLR-derived supernatants  from RA and normal subjects (mean control counts of =52,214 cpm). 
Error bars represent the SEM of quadruplicate cultures. The numbers  of subjects tested  in each 
group are shown above the bars. 180  IMPAIRED  REGULATION OF  EPSTEIN-BARR  VIRUS OUTGROWTH 
FIo.  6.  Physicochemical  properties  of  the  inhibitory  factor  in  auto-MLR  supernatants.  The 
supernatant was dialyzed for 24 h at 4°C against RPMI 1640 with multiple changes of the medium. 
An acid-treated supernatant was prepared by dialysis at 4°C for 18 h against pH 2 glycine buffer 
followed by an additional  18 h dialysis against RPMI  1640 to remove excess acid. Thermal stability 
of the inhibitory activity was evaluated by heating the supernatants in a water bath at 56°C for 30 
and 60 min. The treated supernatants were tested for suppression of EBV-induced B cell prolifera- 
tion.  The  data  are  expressed as  the  mean  percent  suppression of [3H]thymidine  incorporation 
compared with control cultures at  10 d post-EBV infection. Treatment of allo-MLR supernatants 
produced the same results. 
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Fro.  7.  The  ability  of Sephadex G-100  fractions of a  supernatant  from normal  auto-MLR  to 
suppress  EBV-induced  B  cell  proliferation.  Molecular-weight  markers  included  bovine  serum 
albumin (68,000  mol wt), ovalbumin (44,000  mol wt), and soybean trypsin inhibitor (21,500  mol 
wt). [aH]Thymidine incorporation was measured 10 d post-EBV infection. Results are expressed as 
the mean counts per minute of triplicate cultures. 
interferon.  Interferon was  measured  in  18  MLR supernatants  chosen because they 
gave  various  amounts  of  suppression  of  EBV-induced  B  cell  proliferation.  The 
supernatants  were produced by RA and  normal cells  in  autologous and  allogeneic 
MLR.  Their  range  of suppression  was  0-90%,  and  interferon  levels  varied  from 
undetectable to 37 U/ml  (units are determined as equivalents to the antiviral effect HASLER  ET AL.  181 
NI  RA 
----  70  o 
50 
"6  30 
8 
0 ......... 
-10  NonT  AC~epL  NOnT  AC~d~DI. 
NonT  N~T 
MLR Stimulator  Cells 
Fro.  8.  The effect of removal of AC from mononuclear cell populations on the production of a 
supernatant  inhibitory factor in auto-MLR. Supernatants  collected at  72 h  were tested for their 
ability to suppress EBV-induced B cell proliferation. Normal (©) and RA (A) T cells were stimulated 
with autologous non-T cells before and after removal of AC by passage  through Sephadex G-10 
columns.  Results are expressed  as the mean percent suppression  of [SH]thymidine  incorporation 
compared with control cultures at 10 d post-EBV infection (mean control counts =  69,055 cpm). 
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FIG. 9.  The  effect of NIH  standard  IFN  (©),  IFNB  (Z~), IFN7  (D)  on  EBV-induced  B  cell 
proliferation.  Interferon  preparations  were  added  in  concentrations  indicated  to  EBV-infected 
normal non-T lymphocytes.  Results are expressed as the mean percent suppression  of [3H]thymidine 
incorporation  of quadruplicate  samples  compared  with  the  control  culture  at  10  d  post-EBV 
infection (mean control counts =  79,169 cpm). The correlation coefficient  (r = 0.96) was calculated 
using log2 of the interferon concentrations. 
of the international standard  for alpha interferon). There was a  significant correlation 
between  the  suppressive  activity  of  the  individual  supernatant  and  its  interferon 
content  (r =  0.63;  P  <  0.01).  Interferon was below the level of detection in all of the 
tested  RA  auto-MLR  supernatants.  If the  inhibitory  activity  we  are  measuring  is 
mediated by interferon, then addition of small amounts of purified interferon to EBV- 
infected  B  cells should  mimic  the  inhibitory  action  of auto-MLR  supernatants.  In 
fact, human  alpha and beta interferons  (National Institutes of Health standards)  and 
two  preparations  of human  gamma  interferon  caused  a  50%  suppression  of EBV- 
induced  B  cell proliferation with ~2-3  interferon U/ml  (Fig. 9). 182  IMPAIRED  REGULATION  OF  EPSTEIN-BARK  VIRUS  OUTGROWTH 
FIO.  10.  The effect of antibodies to  various interferons on the inhibition of EBV-induced  B cell 
proliferation  by human alpha interferon  (5  IU/ml);  human gamma interferon  (5  IU/ml);  and a 
normal auto-MLR supernatant diluted  1:2.  The  inhibitory  factors  (untreated  or after a  60-rain 
preincubation with the antiserum indicated) were added to EBV-infected non-T cells. [3H]Thymi- 
dine incorporation was measured at  10 d  post-EBV infection. Results are indicated as the SEM of 
quadruplicate culture. 
TABLE  II 
Neutralization  of Auto-MLR Supernatant-mediated  Inhibition  of EB V-induced 
B  Cell Proliferation by Monoclonal Antibody  to Human Gamma Interferon * 
Antibody  [3H]thymidine  Percent sup- 
Supernatant  dilution  incorporation:~  pression§ 
Medium 
Auto-MLR,  1:2 
Auto-MLR,  l:8 
mean cpm + SEM 
--  59,824 +  3,136  -- 
1:30,000  52,717 ±  3,132  -- 
1:3,000  61,312 ±  2,602  -- 
1:300  53,783 ±  3,732  -- 
--  33,587 ±  508  44 
l:30,000  39,404 ±  1,332  25 
1:3,000  61,031  ±  4,251  1 
1:300  59,647 ±  5,218  0 
--  44,773 +  1,012  25 
1:30,000  55,020 +  2,142  0 
1:3,000  64,177 ±  5,432  0 
1:300  62,277 +-  1,222  0 
* Fresh medium or auto-MLR supernatant diluted 1:2 or 1:8 was preincubated 
with routine IgM monoclonal antibody to human gamma interferon at the 
dilutions indicated and then added to EBV-infected non-T cells as described 
in Materials and Methods. 
:~ [3H]Thymidine incorporation was assessed 10 d  post-EBV infection and the 
data expressed as the mean +  SEM of quadruplicate cultures. 
§ Data is expressed as percent suppression as compared with control cultures 
treated with some antibody dilution calculated as described in Materials and 
Methods. 
The  physical  properties  of the  inhibitory  factor  in  the  auto-MLR  supernatants  are 
similar  to  those  of gamma  interferon.  To  determine  whether  gamma  interferon  is the 
active  factor,  the  supernatants  were  reacted  with  antibodies  to  human  interferons. 
The  inhibitory  factor's  action  was  blocked  by  antiserum  to gamma  interferon  but  not 
by  standard  NIH  antisera  to  alpha  interferon  (Fig.  10)  or  beta  interferon  (data  not 
shown).  Although  the  antiserum  against  alpha  interferon  had  no  effect  on  the 
inhibitory  activity  of  the  auto-MLR  supernatant,  it  completely  neutralized  the HASLER  ET  AL.  183 
suppressive activity of leukocyte interferon. The auto-MLR  inhibitory lymphokine 
activity was  also  blocked  by a  murine  IgM  monoclonal  antibody against  human 
gamma interferon in a  dose-related fashion  (Table II). Control IgM ascites had no 
effect on  the  inhibitory activity of MLR  supernatants.  In  addition,  the  anti-viral 
effect of the auto-MLR supernatants in the interferon assay was completely neutral- 
ized with goat anti-human gamma interferon but not affected by sheep anti-human 
alpha interferon (data not shown). Anti-interferon preparations had no direct effect 
on EBV-induced B cell proliferation. Thus, the physicochemical properties, functional 
characteristics,  and  reactivity with  specific polyclonal and  monoclonal  antibodies 
identify this MLR-derived lymphokine as human gamma interferon. 
To  determine whether the  effects of gamma  interferon on  EBV-induced  B  cell 
proliferation might  reflect a  virus-specific event or a  more general  effect on B  cell 
activation, auto-MLR supernatants generated by normal or RA cells were tested for 
inhibitory activity to  B  cells  stimulated  by another T  cell-independent  activator, 
Staphylococcus bacteria strain Cowan I  (Fig. 5 B). Auto-MLR supernatants from 11 
normal blood donors and from 11 RA subjects were equally suppressive to Cowan I- 
induced B cell proliferation (normal 58 ±  4%; RA 62 ±  5%). Therefore, RA cells can 
generate other potentially immunoregulatory suppressor factors in response to auto- 
logous lymphoid cell stimulation, although they do not produce gamma interferon. 
The factor(s) involved in the regulation of Cowan I-induced B cell proliferation has 
distinct physicochemical characteristics from gamma interferon, it is stable to 56°C 
treatment, and its activity is lost after dialysis. 
Discussion 
The results of these experiments lead to two conclusions of interest:  (a) normal T 
cells  activated  in  autologous  and  allogeneic  MLR  produce  sufficient  amounts  of 
gamma interferon to inhibit in vitro EBV-induced B cell proliferation; and (b) RA T 
cells  are  specifically deficient  in  their ability  to  generate  gamma  interferon when 
stimulated by autologous cells, but are capable of doing so, and do so normally, when 
stimulated by allogeneic cells. The inhibitory effect of gamma interferon parallels the 
characteristics of T  cell-mediated early-phase regulation of EBV-induced B lympho- 
blast transformation (1, 3, 4). 
Using a microassay with cells that are relatively sensitive to gamma interferon (22), 
we detected small amounts of interferon activity (4-27 U/ml)  in supernatants from 
most normal auto-MLR collected at 72 h. There was a significant correlation between 
this activity and the inhibition of EBV-induced B cell proliferation. The RA auto- 
MLR supernatants lacked both EBV proliferation inhibitors and interferon activity. 
The inhibition of EBV-induced B cell proliferation is itself a sensitive and reproducible 
interferon  assay;  2-3  U/ml  of either  alpha,  beta,  or  gamma  interferon  reduces 
proliferation N50%  and  this  effect is  abrogated  by the corresponding type-specific 
antibody to interferon. 
Thorley-Lawson (23)  demonstrated  that  T  cells  from normal  adults  are  able  to 
delay outgrowth  of EBV-infected B  cells and  to suppress  the  EB  nuclear antigen 
expression, if the  interactions with  the  EBV-infected cell occurs within  24 h  post- 
infection. More recent data suggest that this early suppressive event can be mediated 
by a lymphokine with properties of human leukocyte alpha interferon (5). We confirm 
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Lawson had to add ~ 1,000 U of alpha interferon to achieve 50% inhibition and 1,000 
U  of antibody added to that interferon was needed to block his supernatant activity. 
Our EBV-induced B cell  proliferation assay required only 1-3 U  of alpha interferon 
for 50% inhibition. The inhibitory activity in our auto- and alIo-MLR supernatants 
differs from leukocyte interferon in its molecular weight, heat lability, and sensitivity 
to acid at pH 2. It also differs somewhat in the kinetics of its activity, retaining the 
capacity to inhibit  EBV-induced proliferation  up to  72 h  after viral  infection. The 
reason  for these discrepancies may relate  to Thorley-Lawson's use of EBV-infected 
cells to provoke interferon production where we used normal non-T cells as stimulators. 
The requirement  for prior exposure to EBV in the responder T  cells  (5)  supports a 
role  for EBV antigens  and  suggests  that  virus-related  membrane  antigens  such  as 
lymphocyte-defined membrane  antigen  could be  responsible  for stimulating  alpha 
interferon production. 
The  physicochemical  properties  of  the  auto-MLR  supernatant  factor  are  like 
undenatured  human gamma interferon, which is known to be released  into culture 
supernatants  during allogeneic MLR, but has not been found when the stimulus  is 
autologous lymphocytes (24).  Two separate  gamma interferon preparations  (17,  18) 
were  tested  for  inhibitory  activity;  both  preparations  were  able  to  suppress  EBV- 
induced  B  cell  proliferation  50%  at  a  concentration of ~2-3  interferon  U/ml.  We 
found  that  interferons  alpha  and  beta  also  effectively inhibit  EBV-induced B  cell 
proliferation, but antisera to those interferons do not block the inhibitory activity in 
auto-MLR supernatants.  In contrast,  antiserum  to human gamma interferon  elim- 
inates the auto-MLR-derived inhibitory activity; and this finding was confirmed with 
a monoclonal antibody against human gamma interferon (19). Antiviral activity was 
also  removed  from  the  auto-MLR  supernatants  by  treatment  with  antiserum  to 
human gamma interferon. Taken together, these experiments identify the regulatory 
factor in autologous and allogeneic MLR supernatants that inhibits EBV-induced B 
cell proliferation as human gamma interferon. T  cells from patients with rheumatoid 
arthritis  are  defective  in  their  ability  to  generate  gamma  interferon  during  the 
autologous MLR, which may explain, at least in part, the diminished capacity of RA 
T  cells to control EBV-induced B lymphoblast transformation (3, 4). 
RA  T  cells  can  make  gamma  interferon  and  do  so  in  normal  amounts  when 
stimulated by allogeneic cells. Thus, the defect in RA appears to reside in the unique 
cell-cell  interactions that characterize the autologous MLR. Surprisingly, the prolif- 
erative response induced by the auto-MLR does not correlate with  the amounts of 
factor produced. The mean  DNA synthetic response of RA cells  in  the auto-MLR 
was not significantly different from the mean response in normal cell populations, nor 
was there a  correlation between  the auto-MLR proliferative response on day 7 and 
the gamma interferon activity of day 3 supernatants in RA patients or normal blood 
donors. Most striking was the finding that adherent cell depletion of the RA non-T 
cells led to a marked increase in gamma interferon production while the proliferative 
response fell sharply. 
Diminished gamma interferon generation by RA cells cannot be explained by the 
effects of either  chronic inflammatory disease  or drug therapy.  Cells  from patients 
with  active  spondyloarthritides,  all  of whom  had  chronic joint  disease  of similar 
severity and duration as the RA patients and who were being treated with nonsteroidal 
anti-inflammatory  medications,  produced  gamma  interferon  in  the  auto-MLR  as HASLER  ET  AL.  185 
effectively as cells from healthy donors. Furthermore, cells from RA subjects receiving 
corticosteroids, gold, or D-penicillamine did not differ from others with RA in their 
inability to generate gamma interferon in the auto-MLR. None of the patients used 
in these studies were receiving other immunosuppressive drugs. 
Supernatants of activated lymphocytes are known to contain a  variety of lympho- 
kines, some with stimulatory capacities and others suppressive (reviewed in 25,  26). 
We considered the possibility that a  difference in  the balance between these effects 
might explain the discrepancy observed when RA and normal T  cells were stimulated 
by autologous mononuclear cells. However, mixing nonsuppressive RA cell-produced 
MLR supernatants with inhibitory supernatants from normal cells failed to demon- 
strate any signs of competition. Thus, the RA cells do not appear to be producing a 
disproportionate amount of a "helper" factor that overwhelms the suppressor; nor are 
they producing an inhibitor of gamma interferon. 
Interferons have growth inhibitory as well as anti-viral properties. We were inter- 
ested in determining whether the striking abnormality in the RA auto-MLR super- 
natant  factors was limited to EBV-induced  lymphoblast transformation or reflected 
a broader defect in control of cell proliferation. Because EBV activates B cells directly 
without  requiring the participation of T  cells  (27,  28), we studied  the effects of the 
RA  auto-MLR  supernatants  on  B  cell  proliferation  induced  by  Staphylococcus 
bacteria strain Cowan I, which  is also a  relatively T  cell-independent  response  (29, 
30).  In marked contrast with the results obtained with EBV as the B cell stimulant, 
autologous MLR supernatants from RA patients contain potent inhibitors of Cowan 
I-induced  B  cell proliferation, equivalent  to normal control supernatants.  We have 
not yet characterized the material responsible for inhibiting Cowan I-induced B cell 
proliferation, but its physicochemical characteristics differ from gamma interferon. 
Cultured  EBV-infected  B  lymphocytes  become  immunoglobulin-secreting  cells. 
Tosato et  al.  (31)  have demonstrated  that  RA T  cells cannot  suppress  autologous 
EBV-induced immunoglobulin-secreting cells, but can regulate their allogeneic coun- 
terparts, which  they have attributed  to a  specific regulatory RAT  cell defect. The 
regulator RAT  cells that we have studied are present and can respond normally to 
autologous B cells.  The regulatory defect depends on the RA T  cells interacting with 
autologous  adherent  cells.  Our  more recent  results  2 demonstrate  that  the  adherent 
cell effects are prostaglandin mediated and the regulatory defect reflects an enhanced 
sensitivity of RAT  cells (or a T  cell subset)  to prostaglandin. 
Summary 
T  cells of patients  with  rheumatoid  arthritis  (RA)  do  not  control  the  rate of B 
lymphoblast transformation induced by Epstein-Barr virus (EBV) as efficiently as T 
cells  from  healthy  individuals;  thus,  Iymphoblast  cell  lines  are  established  more 
readily in RA lymphocytes in vitro after EBV infection.  In the present experiments, 
we have asked whether this T  cell regulation can be reproduced by lymphokines. We 
found  that  normal  T  cells,  activated  in  allogeneic  or  autologous  mixed  leukocyte 
reactions  (MLR),  produce  lymphokines  that  inhibit  in  vitro  EBV-induced  B  cell 
2 Hasler, F., H. G. Bluestein, N. J. Zvaifler, and L. B. Epstein. Analysis of the defects responsible for the 
impaired regulation of EBV-induced B-cell proliferation by rheumatoid arthritis lymphocytes. II. Role of 
monocytes and the increased sensitivity of  rheumatoid arthritis lymphocytes to prostaglandin E. Manuscript 
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proliferation.  Allogeneic MLR  supernatants  inhibited  EBV-induced  DNA synthesis 
62 +__ 4% (mean +_ SE) at  10 d  post-infection, whereas autologous MLR supernatants 
suppressed  it  50  +_-  3%.  RA  T  cell  supernatants  produced  in  an  allogeneic  MLR 
suppressed  as well  as normal T  cell  supernatants  (64 __  5%  inhibition).  In contrast, 
supernatants  from RA autologous MLR  had little  inhibitory activity.  EBV-induced 
DNA  synthesis  at  10  d  was  reduced  only  8  +-  3%,  compared  with  the  50  +  3% 
suppressive activity of normal autologous MLR  supernatants.  The magnitude of the 
proliferative responses in the autologous MLR generating the lymphokines was similar 
in  the  normal  and  RA populations.  After depletion  of adherent  cells  from the  RA 
auto-MLR  stimulators,  supernatant  inhibitory  activities  increased  to normal  levels 
(from  11  +  6  [SE] to 52 +-- 6% [SE]). 
The  inhibitory  factor  involved  in  the  regulation  of in  vitro  EBV  infection  is  a 
protein  with a  molecular weight of ~50,000.  Its activity is eliminated  by heating at 
56°C and by exposure to acid at pH 2. The inhibitory activity is blocked by mixing 
the MLR  supernatants  with a  polyvalent antisera or monoclonal antibodies  specific 
for human  gamma interferon.  Gamma interferon  produced by activating T  cells  in 
allo- or auto-MLR can reproduce T  cell-mediated regulation of EBV-induced B cell 
proliferation, and the failure of RA auto-MLR to generate that lymphokine parallels 
the  defective T  cell  regulation  of EBV-induced  B  cell  proliferation  characteristic  of 
RA lymphoid cells. 
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